Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Disapointed and mostly in the dark.

<< Previous

Bullboard Posts

Next >>

Comment by palinc2000on Feb 24, 2022 4:31pm

116 Views

Post# 34459571

RE:RE:RE:RE:RE:Disapointed and mostly in the dark.

JFM said that hirinfg a sirNA specialist was the nearest thing to confirm that POC had been reached,,,, I have never in my life seen a supposed scientist base his scientitic opinions on tea leaves,,,,,,If you read his past posts that is his way to draw conclusions and I think some here have been mislead by such gross negligence,,,,BTW I have never been a believer in yhis charlatant

scarlet1967 wrote: Your personal expectations are not facts, based on those sortilin expression levels(facts) they now they can target cancers with best potential safety/efficacy results. The issue is posters like yourself with delusional and none significant expectations are disappointed so they are bailing out. They enrolled all comers so going forward they target most suitable (for their Sort1 technology)cancers that's the fact you seem not to grasp!

jfm1330 wrote: The phase Ia is at the worst case scenario level that is not a plain failure. I hate the study design mixing all kind of sortilin expression levels. They have data that we don't have, and it frustrates me. We are mostly in the dark about what is going on, except to now know that 300 mg/m2 is the best possible MTD we can expect. The problem, is that it is also the lowest possible significative MTD. I was expecting 420 mg/m2 as the minimal MTD. Now it's much lower than that. This is the main negative news we learned today.

jfm1330 wrote:

SPCEO1 wrote: What changed today from your perspective and how did it lead you to be " mostly in the dark"?

As you have pointed out, and I agree, most everything positive for the stock depends upon a good result for the phase 1 trial. It looks like we will have to wait another 2-3 months to get the facts you are looking for.

jfm1330 wrote: I listen to the call. If you have a realistic and positive scenario based on facts, not wishful thinking, put it forward clearly because personally I don't see it. Again, no rose-colored glasses. I want something based on facts that would lead you to think that this stock will go up in the next year. Again, no wishful thinking. FACTS!!!